Phase 3 PIVOT-PO trial of tebipenem HBr remains on track to complete enrollment in 2H 2025Reiterate cash runway into mid-2026; Q3 2024 ending ...
In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback